Eleni Efstathiou

Houston Methodist — United States

Medicine · Health Sciences

62h-index21.7kcitations411works8.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(279), Radiopharmaceutical Chemistry and Applications(86), Cancer, Lipids, and Metabolism(86), Prostate Cancer Diagnosis and Treatment(54), Cancer Genomics and Diagnostics(46)

Publications411 total

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Nature Medicine·2025· 12 citedOpen Access
Disease Detection Rate of Combination Ga-68 PSMA-PET/CT and Whole-Body MRI in Biochemical Recurrence After Prostatectomy
Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition·2025
Barriers and solutions for healthcare professionals to involve patients as partners in oncology research: Project RISE
Future Oncology·2025· 1 citedOpen Access
Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.
Journal of Clinical Oncology·2025· 14 cited
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
European Urology Oncology·2025· 11 citedOpen Access
IP26-28 COMPARISON OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH LUTEINIZING HORMONE RELEASING HORMONE AGONISTS VERSUS ANTAGONISTS IN THE US: AN ANALYSIS OF THE TRINETX DATABASE
The Journal of Urology·2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
Future Oncology·2025Open Access
The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially‐Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI‐RADS or TNM Staging
The Prostate·2024· 3 citedOpen Access
The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study
Clinical Genitourinary Cancer·2024· 1 cited
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
European Urology·2024· 88 citedOpen Access
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial
European Urology·2024· 10 citedOpen Access
Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience
Urologic Oncology Seminars and Original Investigations·2024
Perception of cure in prostate cancer: human-led and artificial intelligence-assisted landscape review and linguistic analysis of literature, social media and policy documents
ESMO Open·2024Open Access
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin ineligible muscle invasive bladder cancer
European Urology·2024
Trends in local therapy utilization and survival of patients with de-novo metastatic prostate cancer treated by hormone therapy with or without systemic therapy intensification with chemotherapy.
Journal of Clinical Oncology·2024· 1 cited
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
Journal of Clinical Oncology·2024· 5 cited
Patient-reported outcomes (PRO) in patients (pts) with <i>BRCA1/2</i>-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study.
Journal of Clinical Oncology·2024· 2 cited
MSR150 Artificial Intelligence (AI) in Performing Landscape Review and Linguistic Analysis for Curative Intent in Prostate Cancer (PC)
Value in Health·2023· 1 cited
1233 Impact of infections occurring in patients receiving immune checkpoint inhibitors for renal cell carcinoma (RCC)
Regular and Young Investigator Award Abstracts·2023Open Access
1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
Annals of Oncology·2023· 2 citedOpen Access
page 1 of 21Next →

Frequent Co-authors

Christopher J. Logothetis(20), Fred Saad(19), Karim Fizazi(18), Howard I. Scher(14), Johann S. de Bono(13), Eric J. Small(12), Patricia Troncoso(12), Dana E. Rathkopf(11), Gerhardt Attard(11), Ana M. Aparicio(11), Charles J. Ryan(10), Cora N. Sternberg(10), Kim N.(9), Neal D. Shore(9), Robert J. Jones(8), Tomasz M. Beer(8), Michael J. Morris(8), Silke Gillessen(8), Bertrand Tombal(8), Himisha Beltran(7)